Incorporating a Patient Dichotomous Characteristic in Cancer Phase I Clinical Trials Using Escalation with Overdose Control

Table 4

EWOC with no Covariate. Design operating characteristic with respect to safety and efficiency of the trial.

𝛾0=𝛾1	0.2	0.4	0.6	0.8
Proportion of DLTs	0.3243	0.2939	0.2527	0.2109
Proportion of DLTs in group A	0.3251	0.2944	0.2515	0.2083
Proportion of DLTs in group B	0.3236	0.2934	0.2539	0.2134
Proportion overdosed in group A	0.2755	0.2108	0.0774	0.0023
Proportion overdosed in group B	0.2761	0.2050	0.0749	0.0026
Bias (𝛾1)	−0.0119	−0.0197	−0.0537	−0.1198
MSE (𝛾1)	0.0353	0.0684	0.1032	0.1537